News NewsOur Company DuPont Nutrition & Biosciences to Showcase Innovative Ingredient Solutions at SupplySide West New innovations range from plant-based capsule delivery mechanisms to premium probiotic formulations for cognitive health WILMINGTON, Del.,...
ROCHESTER, N.Y., July 15, 2019 – DuPont (NYSE: DD) today announced the opening of a new state-of-the-art probiotics fermentation unit at its Rochester, New York, facility. Construction of the unit was completed in March as part of an overall $100MM investment to expand probiotics capacity. The facility is now producing high-quality probiotics for the dietary supplement and food and beverage industries, which have the potential to provide health benefits to consumers of all ages.
WILMINGTON, Del., April 25, 2019 – It is estimated that nearly 3 million newborns and 1.2 million children suffer from sepsis globally each year1, with limited effective forms of prevention currently available. To help combat this, DuPont Nutrition & Biosciences (DuPont), the global leader in probiotics, will provide clinical trial probiotic and prebiotic products to the Centre for Global Child Health at The Hospital for Sick Children (SickKids) in Toronto for its research on the effects of probiotics on sepsis in infants.
ROCHESTER, NY, March 28, 2019 – DuPont today announced it has completed construction on a new, state-of-the art probiotics fermentation unit at its Rochester, New York, facility. The unit, now largest in the world, is part of a multiphase nearly $100 million investment to expand probiotics capacity and enhance the company’s leadership in delivering high-quality, clinically documented probiotics to dietary supplement and food and beverage manufacturers.
DuPont Releases Clinical Study Results that Demonstrate Benefits of High-Potency, Multi-Strain Probiotic Formulations
KANTVIK, Finland, March 21, 2019 – Results from a clinical trial performed by Taverniti and colleagues from the University of Milan (IT) suggest that ingesting higher doses of multispecies probiotic formulations may permit higher, earlier and longer recovery of probiotics in feces of healthy adults.
DuPont Nutrition & Health and Lonza Specialty Ingredients Announce Joint Agreement in Human Milk Oligosaccharides
COPENHAGEN, Denmark, Feb. 27, 2019 – DuPont Nutrition & Health and Lonza Specialty Ingredients announce an agreement under which the leading biotechnology and specialty ingredient company Lonza will manufacture and supply CARE4U™ 2’-FL – a human milk oligosaccharide (HMOs). This strategic manufacturing collaboration reinforces market confidence in the supply and premium quality of this specialty ingredient.